BTIG analyst Justin Zelin downgraded Poseida Therapeutics (PSTX) to Neutral from Buy after Roche (RHHBY) agreed to acquire Poseida for $13 per share in cash, comprised of $9 per share in cash at closing and a non-tradeable contingent value right, or CVR, to receive up to $4 per share in cash upon achievement of specific milestones. The firm views the deal terms as “very favorable to both Poseida shareholders and Roche,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Poseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR
- Poseida Therapeutics Advances in Cell Therapy Innovations
- Poseida Therapeutics holds virtual R&D Day
- Poseida Therapeutics Reports Strong Q3 2024 Progress